Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

By P. V. van Doorn, L. Ruts, B. Jacobs. Lancet Neurology, 2008

823 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Global Epidemiology of Campylobacter Infection (2015, background): “GBS is a neurologic condition characterized by a progressive symmetrical weakness in the limbs, with or without hyporeflexia, which can also affect respiratory and cranial nerve-innervated muscles (180).”
Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. (2014, background): “…the high variability of Guillain- Barré syndrome, including variants, 'formes frustes' and overlap syndromes, with an equally large variation in type of preceding infections and specificity of antibodies to nerve glycolipids (Hughes and Cornblath, 2005; Willison, 2005; van Doorn et al., 2008).”
Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. (2014, background): “Based on the affected nerves and conductance pathophysiology, GBS is classified into three major subtypes (294, 499, 577): acute inflammatory demyelinating polyneuropathy (AIDP), acute motor (or motor/sensory) axonal neuropathy (AMAN or AMSAN), and Miller-Fisher Syndrome (MFS), the last of which dis”